Hyperuricemia Clinical Trial
Official title:
The Effects of Rhus Coriaria L. on Serum Uric Acid Levels
The aim of this study is to evaluate the effects of Rhus coriaria L. (Rhus) commonly known as "Somagh" on serum uric acid levels.
Rhus coriaria L.(Rhus) is a well-known spice widely consumed in the world which has also been
utilized extensively for medicinal purposes. The antioxidant components of this plant made it
a favorable target for laboratory and animal studies in different conditions such as
oxidative stress cytotoxicity, diabetes and hyperlipidemia. Rhus (Somagh) is found in
temperate and tropical regions worldwide, often growing in areas of marginal agricultural
capacity. Rhus is used as an herbal remedy in traditional medicine because of its assumed
analgesic, antidiarrheic, antiseptic, anorexic and antihyperglycemic properties. The fruits
of Rhus contain flavonols, phenolic acids, hydrolysable tannins, anthocyans and organic acids
such as malice, citric and tartaric acids. Some studies have shown that polyphenols could
have beneficial effects on cardiovascular disease and cancer and could be regarded as
bioactive compounds with a high potential health-promoting capacity. Phenolic compounds
inhibit lipid peroxidation, scavenge the superoxide anion and hydroxyl radical, and enhance
the activities of detoxifying enzymes.
Uric acid (UA; 7,9-dihydro-1H-purine-2,6,8(3H)-trione) has been implicated as a risk factor
and cause of numerous disease states. Some disease states, such as gout, hypertension, and
cardiovascular disease, have been shown to result when UA levels in the blood are too high.
Hyperuricemia predicts the development of hypertension in the general population, and an
independent positive correlation between UA levels and the occurrence of hypertension has
been reported. Hyperuricemia may also be a risk factor for cardiovascular disease, myocardial
infarction, and stroke.
The manipulation of serum UA levels has become a popular strategy in the treatment of a
variety of diseases. This is either accomplished through dietary and lifestyle changes or
through treatment with UA reducing drugs.
The aim of this study is to evaluate the effects of Rhus coriaria L. (Rhus) commonly known as
Somagh on serum uric acid levels.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05434858 -
Imagery as Biomarker of Gout
|
N/A | |
| Completed |
NCT04060173 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671
|
Phase 1 | |
| Recruiting |
NCT05504083 -
Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients
|
Phase 2 | |
| Completed |
NCT04966325 -
Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects
|
Early Phase 1 | |
| Completed |
NCT01407874 -
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
|
Phase 2 | |
| Completed |
NCT00995618 -
Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia
|
Phase 2 | |
| Completed |
NCT00288158 -
Primary Prevention of Hypertension in Obese Adolescents
|
Phase 2 | |
| Terminated |
NCT04987294 -
Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease
|
Phase 2 | |
| Completed |
NCT04236219 -
ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT06189404 -
Effect of Tigulixostat on the Pharmacokinetics of Theophylline
|
Phase 1 | |
| Recruiting |
NCT05586958 -
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
|
Phase 3 | |
| Recruiting |
NCT06084585 -
The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia
|
N/A | |
| Recruiting |
NCT06056570 -
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04586803 -
Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02959918 -
Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
|
Phase 2 | |
| Not yet recruiting |
NCT02944214 -
Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients
|
N/A | |
| Completed |
NCT02557126 -
Study of URC102 to Assess the Safety and Efficacy in Gout Patients
|
Phase 2 | |
| Active, not recruiting |
NCT01021241 -
Safety and Efficacy Study of Intravenous Uricase-PEG 20
|
Phase 1 | |
| Completed |
NCT00756964 -
Lowering Serum Uric Acid to Prevent Acute Kidney Injury
|
Phase 2 | |
| Terminated |
NCT00607152 -
Rasburicase (Fasturtec) Registration Trial
|
Phase 3 |